fbpx
Connect with us

News

Lapsi Health raises US$600k to develop digital biomarkers

Avatar photo

Published

on

Dutch medtech firm Lapsi Health has raised US$600k in a pre-seed funding round to advance its work to develop  new digital biomarkers based on auscultatory sound.

The funding round was led by several tech investors spanning Europe and the Middle East, including those from the Netherlands, Finland, the US, Uruguay and the UAE.

Lapsi is working to develop new digital biomarkers based on sounds acquired by the first continuous wearable stethoscope, developed by its team in Finland. The acquired sounds have the potential to be analysed by several algorithmic methods and to be converted into biomarkers.

The new funds will be used to develop the first technological principles of its solution and to enter clinical validation trials. Specifically, the company will focus on auscultatory sound acquisition, analytics and remote patient monitoring.

Jhonatan Bringas Dimitriades, CEO at Lapsi Health and an expert in digital health and biomarkers, said: “We have been able to secure a fast investment to be able to develop solutions that are very necessary for chronic patients in several medical specialties, worldwide.

“Our investment partners have a crucial role in the future of Lapsi Health, not only from the financial perspective but also opening doors to the company for potential customers, partners and collaborators.

“This technology will represent a usage of auscultatory sound in a way that is not currently being used, creating a new generation of Digital Biomarkers.”

Chief medical officer Diana van Stijn – a leading expert in digital therapeutics and paediatrics – said: “Data driven decisions are the next step to improve healthcare, patient empowerment, clinical intelligence and to make clinical research more democratised. These are the ideals that inspired us to create Lapsi Health.”

Other members of the team include Seamus Holohan, business development advisor and executive, and Rodrigo Alvez, CTO.

Advisory board members include Craig Lipset, former head of innovation at Pfizer and current co-chair of the Decentralized Trials and Research Alliance, and Rafael Grossmann, a “futurist surgeon” and MIT/Singularity faculty member. Also involved are Carlos Sendon and Suzanne Terheggen-Lagro, pulmonologists from Europe and the US respectively, and Aline Noizet, a digital health advisor.

Continue Reading
1 Comment

1 Comment

  1. Pingback: Lapsi Health raised $0.6M to develop digital biomarkers - Health Incubator Helsinki

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories